Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo

Mol Cell Biochem. 2010 Aug;341(1-2):225-33. doi: 10.1007/s11010-010-0453-2. Epub 2010 Apr 8.

Abstract

The overexpression of the type 1 insulin-like growth factor receptor (IGF-1R) has been reported to be associated with malignant transformation, tumor development and chemo- or radioresistance of tumor cells. Previously, we have reported that inhibition of IGF-1R could reverse the radioresistance of human osteosarcoma cells. However, whether inhibition of IGF-1R could enhance chemosensitivity of ostesosarcoma cells is unclear. In this study, lentivirus-mediated shRNA was employed to downregulate endogenous IGF-1R expression to study the function of IGF-1R in chemoresistance of osteosarcoma cells. Results showed that lentivirus-mediated shRNA targeting IGF-1R combined with chemotherapy (CDDP or DTX) could lead to growth suppression of osteosarcoma cells not only in vitro but also in vivo. Moreover, inhibition of IGF-1R gene combined with chemotherapy also synergistically enhanced Caspase-3-mediated apoptosis of osteosarcoma cells. The synergistical enhancement of apoptosis might be associated with downregulation of Bcl-2 and upregulation of Bax in osteosarcoma cells induced by IGF-1R inhibition. Therefore, the overexpression of IGF-1R gene might play important roles in chemoresistance of osteosarcoma cells, and lentivirus-mediated RNAi targeting IGF-1R would be an attractive anti-cancer strategy to chemosensitization of osteosarcoma cell.

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Cells, Cultured
  • Drug Resistance, Neoplasm / drug effects*
  • Genetic Therapy / methods
  • Humans
  • Lentivirus / genetics
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / pathology
  • RNA Interference / physiology*
  • RNA, Small Interfering / administration & dosage*
  • Receptor, IGF Type 1 / antagonists & inhibitors*
  • Receptor, IGF Type 1 / genetics
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • RNA, Small Interfering
  • Receptor, IGF Type 1